Adherium to present at Reach Markets ‘Meet the CEOs’ live event

Melbourne, Australia / Link here – 16 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce its participation in the Reach Markets ‘Meet the CEOs’ live event, being held tomorrow, Wednesday 17th of August 2022. The webinar will open […]

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]

Humanetix – How prepared are you for AN-ACC?

Link Here – As ACFI will be replaced AN-ACC from October 2022, the focus on quality data, systems and interoperability cannot be overlooked. With AN-ACC focusing on individual care needs, providers will need to scramble to obtain client care delivery data with the process between shadow assessments, AN-ACC tools, and ultimately funding delivery to […]

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

  Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]

Acrux’s sixth generic application accepted FDA for review

Melbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]

Adherium submits FDA 510(k) application for next generation Hailie sensor for GSK pMDI inhalers

Melbourne, Australia – 2 August 2022 link here: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects GlaxoSmithKline® (GSK) Ventolin®, Advair®, and Flovent® pressurized metered-dose inhaler (pMDI) users […]